Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 18/20 | 0.64 |
| ▸ | AURKA | O14965 | 15/20 | 0.64 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | BCR | P11274 | 1/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201749 | 0.90 | AURKB (0.64) | AURKBAURKASRCGSK3BABL1 | |
| SCHEMBL1532353 | 0.90 | AURKB (0.53) | AURKBAURKASRCGSK3B | |
| SCHEMBL1299976 | 0.89 | AURKB (0.51) | AURKBAURKASRCGSK3BABL1 | |
| SCHEMBL2203838 | 0.87 | AURKB (0.60) | AURKBAURKASRCGSK3BABL1 | |
| SCHEMBL2204784 | 0.87 | AURKB (0.60) | AURKBAURKASRCGSK3BABL1 | |
| SCHEMBL12338773 | 0.87 | AURKB (0.60) | AURKBAURKASRCGSK3BABL1 | |
| SCHEMBL648099 | 0.87 | AURKA (0.58) | AURKBAURKASRCGSK3BABL1 | |
| SCHEMBL2204846 | 0.86 | AURKB (0.76) | AURKBAURKASRCGSK3BABL1 | |
| SCHEMBL1816236 | 0.85 | AURKB (0.55) | AURKBAURKASRCGSK3B | |
| SCHEMBL12338796 | 0.85 | AURKB (0.57) | AURKBAURKASRCGSK3BABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954277-B1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMA (US) | 2017-01-18 | — | — | EP | disclosed |
| US-8637511-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2292614-A1 | Substituted pyrimidines as aurora kinase inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2011-03-09 | — | — | EP | disclosed |
| EP-1746093-B1 | Process for preparing substituted pyrimidines | VERTEX PHARMA (US) | 2011-02-16 | — | — | EP | disclosed |
| EP-2277876-A1 | Substituted pyrimidines for the treatment of cancer | Vertex Pharmaceuticals Incorporated (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100310675-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
| US-7767672-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-03 | — | — | US | disclosed |
| EP-1954277-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | Vertex Pharmceuticals Incorporated (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20070259869-A1 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-08 | — | — | US | disclosed |
| WO-2007056221-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310675-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | ABL1, PRKDC, MAP3K5 | AURKB 131/4885AURKA 66/4885SRC 239/4885 |
| US-20070259869-A1 | Aminopyrimidines useful as kinase inhibitors | ABL1, PRKDC, MAP3K5 | AURKB 131/4885AURKA 66/4885SRC 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.